APOE and BCHE as modulators of cerebral amyloid deposition: A florbetapir PET genome-wide association study

Molecular Psychiatry

Volumn 19, Issue 3, 2014, Pages 351-357

  Ramanan, V K ^a   Risacher, S L ^a   Nho, K ^a   Kim, S ^a,b   Swaminathan, S ^a   Shen, L ^a,b   Foroud, T M ^a,b   Hakonarson, H ^c   Huentelman, M J ^d   Aisen, P S ^e   Petersen, R C ^f   Green, R C ^g   Jack, C R ^f   Koeppe, R A ^h   Jagust, W J ⁱ   Weiner, M W ^j,k   Saykin, A J ^a,b  

^a INDIANA UNIVERSITY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^d TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f MAYO CLINIC   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

more..

Author keywords

Alzheimer's disease (AD); Amyloid; Apolipoprotein E (APOE); Butyrylcholinesterase (BCHE); Florbetapir (AV 45); Genomewide association study (GWAS)

Indexed keywords

ALPHA1 INTEGRIN; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; CHOLINESTERASE; EPHRIN A5; FLORBETAPIR F 18; GENOMIC DNA; PHOSPHATIDYLINOSITOL 3 KINASE;

ADULT; AGED; ALZHEIMER DISEASE; ARID1B GENE; ARTICLE; BRAIN CORTEX; BRAIN LEVEL; C12ORF75 GENE; CHOLINESTERASE BLOOD LEVEL; CHROMOSOME 19; DNA EXTRACTION; EDIL3 GENE; EFNA5 GENE; ENZYME ACTIVITY; FEMALE; GENE; GENE FREQUENCY; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; IN VIVO STUDY; ITGA1 GENE; ITGA6 GENE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; NFIB GENE; NUAK1 GENE; PET SCANNER; PIK3R1 GENE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENILE PLAQUE; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANILINE COMPOUNDS; APOLIPOPROTEINS E; BUTYRYLCHOLINESTERASE; CEREBRAL CORTEX; ETHYLENE GLYCOLS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FUNCTIONAL NEUROIMAGING; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; PLAQUE, AMYLOID; POSITRON-EMISSION TOMOGRAPHY;

EID: 84894517016     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2013.19     Document Type: Article

References (45)

1. Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer's disease: An appraisal for the development of therapeutics. Nat Rev Drug Discov 2011; 10: 698-712
2. Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: A review of the literature. J Neuropathol Exp Neurol 2012; 71: 362-381
3. Petersen RC, Parisi JE, Dickson DW, Johnson KA, Knopman DS, Boeve BF et al. Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol 2006; 63: 665-672
4. Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC et al. Neuropathology of older persons without cognitive impairment from two community- based studies. Neurology 2006; 66: 1837-1844
5. Sleegers K, Lambert JC, Bertram L, Cruts M, Amouyel P, Van Broeckhoven C. The pursuit of susceptibility genes for Alzheimer's disease: Progress and prospects. Trends Genet 2010; 26: 84-93
6. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM et al. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 280-292
7. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261: 921-923
8. Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer's disease. Neuron 2009; 63: 287-303
9. Furst AJ, Kerchner GA. From alois to amyvid: Seeing Alzheimer disease. Neurology 2012; 79: 1628-1629
10. Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA et al. Use of florbetapir-PET for imaging beta-Amyloid pathology. JAMA 2011; 305: 275-283
11. Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-b plaques: A prospective cohort study. Lancet Neurol 2012; 11: 669-678
12. Weiner MW, Aisen PS, Jack Jr. CR, Jagust WJ, Trojanowski JQ, Shaw L et al. The Alzheimer's disease neuroimaging initiative: Progress report and future plans. Alzheimers Dement 2010; 6: 202-211 e207
13. Jagust WJ, Bandy D, Chen K, Foster NL, Landau SM, Mathis CA et al. The Alzheimer's disease neuroimaging initiative positron emission tomography core. Alzheimers Dement 2010; 6: 221-229
14. Saykin AJ, Shen L, Foroud TM, Potkin SG, Swaminathan S, Kim S et al. Alzheimer's disease neuroimaging initiative biomarkers as quantitative phenotypes: Genetics core aims, progress, and plans. Alzheimers Dement 2010; 6: 265-273
15. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D et al. PLINK: A tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559-575
16. Howie B, Fuchsberger C, Stephens M, Marchini J, Abecasis GR. Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. Nat Genet 2012; 44: 955-959
17. Stein JL, Medland SE, Vasquez AA, Hibar DP, Senstad RE, Winkler AM et al. Identification of common variants associated with human hippocampal and intracranial volumes. Nat Genet 2012; 44: 552-561
18. Péer I, Yelensky R, Altshuler D, Daly MJ. Estimation of the multiple testing burden for genomewide association studies of nearly all common variants. Genet Epidemiol 2008; 32: 381-385
19. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265
20. Johnson AD, Handsaker RE, Pulit SL, Nizzari MM, O'Donnell CJ, de Bakker PI. SNAP: A web-based tool for identification and annotation of proxy SNPs using HapMap. Bioinformatics 2008; 24: 2938-2939
21. Petersen RC. Clinical practice. Mild cognitive impairment. N Engl J Med 2011; 364: 2227-2234
22. Potkin SG, Turner JA, Guffanti G, Lakatos A, Torri F, Keator DB et al. Genome-wide strategies for discovering genetic influences on cognition and cognitive disorders: Methodological considerations. Cogn Neuropsychiatry 2009; 14: 391-418
23. Kendler KS, Neale MC. Endophenotype: A conceptual analysis. Mol Psychiatry 2010; 15: 789-797
24. Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW et al. Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Sci Transl Med 2011; 3: 89ra57
25. Holtzman DM, Morris JC, Goate AM. Alzheimer's disease: The challenge of the second century. Sci Transl Med 2011; 3: 77sr71
26. Koffie RM, Hashimoto T, Tai HC, Kay KR, Serrano-Pozo A, Joyner D et al. Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-beta. Brain 2012; 135: 2155-2168
27. Lehmann DJ, Johnston C, Smith AD. Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset confirmed Alzheimer's disease. Hum Mol Genet 1997; 6: 1933-1936
28. Darvesh S, Hopkins DA, Geula C. Neurobiology of butyrylcholinesterase. Nat Rev Neurosci 2003; 4: 131-138
29. Guillozet AL, Smiley JF, Mash DC, Mesulam MM. Butyrylcholinesterase in the life cycle of amyloid plaques. Ann Neurol 1997; 42: 909-918
30. Lane R, Feldman HH, Meyer J, He Y, Ferris SH, Nordberg A et al. Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease. Pharmacogenet Genomics 2008; 18: 289-298
31. Tasker A, Ballard CG, Joachim C, Warden DR, Okello EJ, Perry RH et al. Butyrylcholinesterase K variant associated with higher enzyme activity in the temporal cortex of elderly patients. Neurosci Lett 2008; 442: 297-299
32. Lane RM, He Y. Butyrylcholinesterase genotype and gender influence Alzheimer's disease phenotype. Alzheimers Dement advance online publication, 10 March 2012; doi:10.1016/j.jalz.2010.12.005
33. Farlow MR, Miller ML, Pejovic V. Treatment options in Alzheimer's disease: Maximizing benefit, managing expectations. Dement Geriatr Cogn Disord 2008; 25: 408-422
34. Sabbagh MN, Farlow MR, Relkin N, Beach TG. Do cholinergic therapies have disease-modifying effects in Alzheimer's disease? Alzheimers Dement 2006; 2: 118-125
35. Darvesh S, Cash MK, Reid GA, Martin E, Mitnitski A, Geula C. Butyrylcholinesterase is associated with beta-Amyloid plaques in the transgenic APPSWE/PSEN1dE9 mouse model of Alzheimer disease. J Neuropathol Exp Neurol 2012; 71: 2-14
36. Darreh-Shori T, Forsberg A, Modiri N, Andreasen N, Blennow K, Kamil C et al. Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer's disease in the brain in vivo. Neurobiol Aging 2011; 32: 2320 e2315-2320.e2332
37. Darreh-Shori T, Modiri N, Blennow K, Baza S, Kamil C, Ahmed H et al. The apolipoprotein E e4 allele plays pathological roles in AD through high protein expression and interaction with butyrylcholinesterase. Neurobio Aging 2011; 32: 1236-1248
38. Lane RM, He Y. Emerging hypotheses regarding the influences of butyrylcholinesterase- K variant, APOE e4, and hyperhomocysteinemia in neurodegenerative dementias. MedHypotheses 2009; 73: 230-250
39. Iwasaki T, Yoneda M, Nakajima A, Terauchi Y. Serum butyrylcholinesterase is strongly associated with adiposity, the serum lipid profile and insulin resistance. Intern Med 2007; 46: 1633-1639
40. Meigs JB, Manning AK, Fox CS, Florez JC, Liu C, Cupples LA et al. Genome-wide association with diabetes-related traits in the Framingham Heart Study. BMC Med Genet 2007; 8(Suppl 1): S16
41. Benyamin B, Middelberg RP, Lind PA, Valle AM, Gordon S, Nyholt DR et al. GWAS of butyrylcholinesterase activity identifies four novel loci, independent effects within BCHE and secondary associations with metabolic risk factors. Hum Mol Genet 2011; 20: 4504-4514
42. Kapranov P, Willingham AT, Gingeras TR. Genome-wide transcription and the implications for genomic organization. Nat Rev Genet 2007; 8: 413-423
43. Bamberger ME, Harris ME, McDonald DR, Husemann J, Landreth GE. A cell surface receptor complex for fibrillar beta-Amyloid mediates microglial activation. J Neurosci 2003; 23: 2665-2674
44. Bomfim TR, Forny-Germano L, Sathler LB, Brito-Moreira J, Houzel JC, Decker H et al. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- Associated Abeta oligomers. J Clin Invest 2012; 122: 1339-1353
45. Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008; 131: 1630-1645.